The core function of the Screening Group (SCR) at IARC is to provide data on the accuracy, reproducibility, efficacy, benefits, harmful effects, and cost-effectiveness of various early detection interventions for breast, cervical, colorectal, and oral cancers, among others, in reducing deaths and improving patientsí quality of life in various settings. These data can then be used to inform and improve the rational use of health-care resources. The Groupís ultimate objective is to guide the development of public health policies for implementing screening in a variety of health-care settings, in particular in low- and middle-income countries (LMICs).
SCR conducts field studies in LMICs to evaluate various early detection methods for breast, cervical, colorectal, and oral cancer control. These initiatives also address the means by which screening services could be scaled up through local public health services. SCR develops various training resources to catalyse and augment capacity building in close collaboration with national institutions and government health services. Through its research programme, SCR generates scientific evidence to support the development of resource-appropriate early detection policies and health systems for the delivery of effective early services. The Cancer Screening in 5 Continents (CanScreen5) project of the Group aims to collect information on characteristics and performance of cancer screening programmes around the world and disseminate such information for informed decision making in cancer screening programmes. For example, the Group significantly contributed also to the evaluation of the safety and efficacy of less than three doses of the HPV vaccine in protecting against cervical cancer.
EMERGENCY: Coronavirus disease (COVID-19) Pandemic16/03/2020
Regular updates on the coronavirus disease (COVID-19) outbreak are available at the WHO website.
New publication: The European response to the WHO call to eliminate cervical cancer as a public health problem08/07/2020
This reports addresses for the first time the question how Europe could answer to the ambitious call from the World Health Organisation to reduce the incidence of cervical cancer to less than 4/100 000/year by reaching, by the 2030 >90, 70 and 90% coverage for HPV vaccination, HPV-based screening and management of screen-positive women, respectively. The occurrence of the COVID-19 pandemic, having interrupted prevention activities temporarily, should not deviate stakeholders from this ambition. The authors of this paper underline the need for a new third edition of EU guidelines for integrated primary and secondary prevention of cervical cancer. View the article.
New publication: Human papillomavirus vaccination: Good clinical practice recommendations from the Federation of Obstetric and Gynecological Societies of India06/07/2020
The Federation of Obstetric and Gynecological Societies of India (FOGSI) convened an expert group on cervical cancer prevention to formulate good clinical practice recommendations (GCPR) with respect to vaccine efficacy and safety, target groups, optimal timing and dosing schedules. Experts concluded that HPV vaccination should be the priority to achieve the elimination of cervical cancer. The introduction of affordable HPV vaccines and reduced dose schedules will improve coverage. View the publication.
New commentary: Two-dose recommendation up to 18 years11/06/2020
In this commentary published in HPVWORLD, Dr Partha Basu and colleagues demonstrate that protection against the vaccine-targeted HPV types (HPV16 and 18) or the cross-protective types (HPV31, 33 and 45) is similar in the 15-18 year-old women irrespective of whether they received two doses or three doses.
View the commentary.
New publication: Correlation Between p16/Ki-67 Expression and the Grade of Cervical Intraepithelial Neoplasias.10/06/2020
This article published in the International Journal of Gynecological Pathology reports the evaluation of the biomarkers p16 and Ki-67 in improving the diagnostic accuracy of cervical histopathology and assess the correlation between p16 expression and human papillomavirus test in different grades of cervical intraepithelial neoplasia (CIN). Authors concluded that dual staining could be used as an adjunctive test to improve the diagnostic accuracy of histopathology. In addition, p16/Ki-67 IHC has a role in guiding management decisions in cases with discordant colposcopy and histopathology diagnoses. View the article.
|Arbyn M., Gultekin M., Morice P., Nieminen P., Cruickshank M., Poortmans P., Kelly D., Poljak M., Bergeron C., Ritchie D., Schmidt D., Kyrgiou M., Van den Bruel A., Bruni L., Basu P., Bray F., Weiderpass E. The European Response to the WHO Call to Eliminate Cervical Cancer as a Public Health Problem. Int J Cancer. 2020 Jul 7.|
|Bhatla N., Meena J., Gupta K., Pal B., Divakar H., Bhalerao S., Peedicayil A., Srivastava S., Basu P., Purandare C.N.; FOGSI Expert Group. Human papillomavirus vaccination: Good clinical practice recommendations from the Federation of Obstetric and Gynecological Societies of India. J Obstet Gynaecol Res. 2020 Jul 6.|
|Mandal R., Ghosh I., Banerjee D., Mittal S., Muwonge R., Roy C., Panda C., Vernekar M., Frappart L., Basu P. Correlation Between p16/Ki-67 Expression and the Grade of Cervical Intraepithelial Neoplasias. Int J Gynecol Pathol. 2020 Jul;39(4):384-390.|